Asitri Dashboard
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 35
Selected: 0
NCT ID | Title | ||
---|---|---|---|
NCT02160626 | Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis | ||
NCT02669862 | A Study of A-101 Solution in Subjects With Common Warts. | ||
NCT03594227 | ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis | ||
NCT03691831 | A Study of A-101 Topical Solution for the Treatment of Common Warts | ||
NCT03148691 | A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis | ||
NCT01986920 | Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis | ||
NCT05791474 | ATI-2231 in Advanced Solid Tumor Malignancies | ||
NCT05279417 | ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA) | ||
NCT03495817 | A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution | ||
NCT04598269 | Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis | ||
NCT02260180 | Study of A-101 for the Treatment of Seborrheic Keratosis | ||
NCT03315689 | Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) | ||
NCT03812510 | Safety Study of A-101 Topical Solution for the Treatment of Common Warts | ||
NCT03759340 | ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) | ||
NCT06648434 | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | ||
NCT03585296 | A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis | ||
NCT05432596 | Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis | ||
NCT05216224 | ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) | ||
NCT05511519 | Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis | ||
NCT03380390 | Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea | ||
NCT03687372 | Study of A-101 Topical Solution for the Treatment of Common Warts | ||
NCT04524858 | Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) | ||
NCT02667236 | A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. | ||
NCT06374459 | Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis | ||
NCT02667275 | A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis | ||
NCT03468855 | A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo | ||
NCT06585202 | Study of ATI-2138 in Adult Participants with Moderate to Severe Atopic Dermatitis | ||
NCT03354637 | A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata | ||
NCT03210337 | A Phase2 of A-101 Topical Solution in Subjects With Common Warts | ||
NCT03551821 | Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata | ||
NCT03487588 | An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses | ||
NCT03278028 | A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts | ||
NCT02667288 | An Open-Label Safety Study of A-101 Solution | ||
NCT03224598 | A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra | ||
NCT04247815 | Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA |